With Forty Seven co-founder at the helm, new biotech spinout launches to target mutations potentially linked to numerous diseases
Mark Chao is going back into biotech — and his new company, launched this morning, is going after mysterious mutations in the blood and how they impact disease.
If the name seems familiar, you might remember Chao as one of the names behind Forty Seven, an immuno-oncology biotech that caught Gilead’s eye a few years back — and ultimately its wallet, when the biotech got bought out by the pharma for $4.9 billion in 2020. Chao then came on board with Gilead as a VP of oncology before leaving to get on board with the new biotech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.